The author reviews the reasons for FDA labeling changes for estrogens and estrogen–progesterone combinations as hormonal therapy; sertraline for depression; and palivizumab as prophylactic therapy for respiratory infections.
You are here
P&T® Journal contents for March 2003
The authors present the results of a survey sent to the directors of MCOs to ascertain their views on chronic pain in their patients.
The first of the new selective cholesterol absorption inhibitors, ezetimibe has been approved for several indications.
Now is the time to order vaccine for the fall flu season. The authors discuss the ways in which many diseases in older adults could be prevented with more effective immunization strategies.